Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2026 · third_quarter · Q3
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Source: Senate LDA
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period.
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
Ensuring Patient Access to Critical Breakthrough Products Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
Ensuring Patient Access to Critical Breakthrough Products Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period.
Ensuring Patient Access to Critical Breakthrough Products Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Ensuring Patient Access to Critical Breakthrough Products Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Ensuring Patient Access to Critical Breakthrough Products Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Ensuring Patient Access to Critical Breakthrough Products Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period.
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period, including S.1717 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Corporate Tax and Tariffs, H.R.1 - One Big Beautiful Bill Act
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Clinical Lab Fee Schedule reform and Medicare coverage of FDA approved breakthrough diagnostics and innovative diagnostics
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period Issues related to Tariffs
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period Issues related to Tariffs
Ensuring Patient Access to Critical Breakthrough Products Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period Issues related to Tariffs
Ensuring Patient Access to Critical Breakthrough Products Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period Issues related to Tariffs
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period, including S.1717 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Corporate Tax and Tariffs, H.R.1 - One Big Beautiful Bill Act
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period Issues related to Tariffs
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period Issues related to Tariffs
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period Issues related to Tariffs
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period Issues related to Tariffs
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and HR 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
VALID Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023
VALID Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and HR 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule
State Strategic Stockpile Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023
State Strategic Stockpile Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
To amend the Public Health Service Act to require the development of a diagnostic testing preparedness plan to be used during public health emergencies, and for other purposes.
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023
To amend the Public Health Service Act to require the development of a diagnostic testing preparedness plan to be used during public health emergencies, and for other purposes.
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Protecting America from Seasonal and Pandemic Influenza Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Protecting America from Seasonal and Pandemic Influenza Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and HR 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and HR 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
VALID Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, SCREENS Act (HR 3916), issues related to 3rd party servicing of medical equipment (Right to Repair), and H. R. 5846 Protecting America from Seasonal and Pandemic Influenza Act of 2023 (the Influenza Act)
VALID Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, SCREENS Act (HR 3916), issues related to 3rd party servicing of medical equipment (Right to Repair), H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and HR 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, SCREENS Act (HR 3916), issues related to 3rd party servicing of medical equipment (Right to Repair), H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
State Strategic Stockpile Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, SCREENS Act (HR 3916), issues related to 3rd party servicing of medical equipment (Right to Repair), and H. R. 5846 Protecting America from Seasonal and Pandemic Influenza Act of 2023 (the Influenza Act)
State Strategic Stockpile Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, SCREENS Act (HR 3916), issues related to 3rd party servicing of medical equipment (Right to Repair), H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
To amend the Public Health Service Act to require the development of a diagnostic testing preparedness plan to be used during public health emergencies, and for other purposes.
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, SCREENS Act (HR 3916), issues related to 3rd party servicing of medical equipment (Right to Repair), H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
To amend the Public Health Service Act to require the development of a diagnostic testing preparedness plan to be used during public health emergencies, and for other purposes.
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, SCREENS Act (HR 3916), issues related to 3rd party servicing of medical equipment (Right to Repair), and H. R. 5846 Protecting America from Seasonal and Pandemic Influenza Act of 2023 (the Influenza Act)
SCREENS for Cancer Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, SCREENS Act (HR 3916), issues related to 3rd party servicing of medical equipment (Right to Repair), and H. R. 5846 Protecting America from Seasonal and Pandemic Influenza Act of 2023 (the Influenza Act)
SCREENS for Cancer Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, SCREENS Act (HR 3916), issues related to 3rd party servicing of medical equipment (Right to Repair), H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Protecting America from Seasonal and Pandemic Influenza Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, SCREENS Act (HR 3916), issues related to 3rd party servicing of medical equipment (Right to Repair), and H. R. 5846 Protecting America from Seasonal and Pandemic Influenza Act of 2023 (the Influenza Act)
Protecting America from Seasonal and Pandemic Influenza Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, SCREENS Act (HR 3916), issues related to 3rd party servicing of medical equipment (Right to Repair), H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and HR 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, SCREENS Act (HR 3916), issues related to 3rd party servicing of medical equipment (Right to Repair), H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2026 · second_quarter · Q2
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2026 · first_quarter · Q1
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2025 · fourth_quarter · Q4
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period Issues related to Tariffs
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2025 · third_quarter · Q3
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period Issues related to Tariffs
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2025 · second_quarter · Q2
Access to and reimbursement of diagnostics in the Medicare program. Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period, including S.1717 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Corporate Tax and Tariffs, H.R.1 - One Big Beautiful Bill Act
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2025 · first_quarter · Q1
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Clinical Lab Fee Schedule reform and Medicare coverage of FDA approved breakthrough diagnostics and innovative diagnostics
(MMM) Clinical Lab Fee Schedule reform and Medicare coverage of FDA approved breakthrough diagnostics and innovative diagnostics (preeclampsia)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2024 · fourth_quarter · Q4
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2024 · third_quarter · Q3
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID)
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2024 · second_quarter · Q2
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID)
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2024 · first_quarter · Q1
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and HR 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID)
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2023 · fourth_quarter · Q4
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, SCREENS Act (HR 3916), issues related to 3rd party servicing of medical equipment (Right to Repair), and H. R. 5846 Protecting America from Seasonal and Pandemic Influenza Act of 2023 (the Influenza Act)
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and HR 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, SCREENS Act (HR 3916), issues related to 3rd party servicing of medical equipment (Right to Repair), H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), White House Office